Literature DB >> 22609885

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.

P Armand, M-M Sainvil, H T Kim, J Rhodes, C Cutler, V T Ho, J Koreth, E P Alyea, E J Neufeld, R Y Kwong, R J Soiffer, J H Antin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22609885      PMCID： PMC3954511          DOI： 10.1038/bmt.2012.94

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Non-transferrin-bound iron during allogeneic stem cell transplantation.

Authors:  L Sahlstedt; F Ebeling; L von Bonsdorff; J Parkkinen; T Ruutu
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

2.  Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Dimitrios P Kontoyiannis; Georgios Chamilos; Russell E Lewis; Sergio Giralt; Jorge Cortes; Issam I Raad; John T Manning; Xin Han
Journal:  Cancer       Date:  2007-09-15       Impact factor: 6.860

3.  Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia.

Authors:  Toshihiro Fukushima; Hiroshi Kawabata; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomoyuki Sakai; Toshioki Sawaki; Yoshimasa Fujita; Masao Tanaka; Yasufumi Masaki; Yuko Hirose; Hisanori Umehara
Journal:  Anticancer Res       Date:  2011-05       Impact factor: 2.480

4.  Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Joanna Rhodes; Marie-Michele Sainvil; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Doreen Hearsey; Ellis J Neufeld; Mark D Fleming; Hanno Steen; Damon Anderson; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-18       Impact factor: 5.742

5.  Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.

Authors:  J B Porter; M S Jaswon; E R Huehns; C A East; J W Hazell
Journal:  Br J Haematol       Date:  1989-11       Impact factor: 6.998

6.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Robert J Soiffer; Joseph H Antin
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

7.  Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.

Authors:  V Pullarkat; S Blanchard; B Tegtmeier; A Dagis; K Patane; J Ito; S J Forman
Journal:  Bone Marrow Transplant       Date:  2008-09-01       Impact factor: 5.483

8.  Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).

Authors:  Uwe Platzbecker; Martin Bornhäuser; Ulrich Germing; Julian Stumpf; Bart L Scott; Nicolaus Kröger; Rainer Schwerdtfeger; Alexandra Böhm; Guido Kobbe; Catrin Theuser; Werner Rabitsch; Peter Valent; Mohamed L Sorror; Gerhard Ehninger; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

9.  Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation.

Authors:  Anuj Mahindra; Brian Bolwell; Ronald Sobecks; Lisa Rybicki; Brad Pohlman; Robert Dean; Steve Andresen; John Sweetenham; Matt Kalaycio; Edward Copelan
Journal:  Br J Haematol       Date:  2009-06-08       Impact factor: 6.998

10.  Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.

Authors:  Yanina Eberhard; Sean P McDermott; Xiaoming Wang; Marcela Gronda; Amudha Venugopal; Tabitha E Wood; Rose Hurren; Alessandro Datti; Robert A Batey; Jeffrey Wrana; William E Antholine; John E Dick; John Dick; Aaron D Schimmer
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113
  10 in total
  10 in total

Review 1.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

2.  Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.

Authors:  Philippe Armand; Haesook T Kim; Johanna M Virtanen; Riitta K Parkkola; Maija A Itälä-Remes; Navneet S Majhail; Linda J Burns; Todd DeFor; Bryan Trottier; Uwe Platzbecker; Joseph H Antin; Martin Wermke
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-24       Impact factor: 5.742

Review 3.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

4.  Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Authors:  Jennifer E Vaughn; Barry E Storer; Philippe Armand; Roberto Raimondi; Christopher Gibson; Alessandro Rambaldi; Fabio Ciceri; Rosi Oneto; Benedetto Bruno; Paul J Martin; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-07       Impact factor: 5.742

Review 5.  Understanding the Potential and Risk of Bacterial Siderophores in Cancer.

Authors:  Valentina Pita-Grisanti; Kaylin Chasser; Trevor Sobol; Zobeida Cruz-Monserrate
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

6.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.

Authors:  Bryan J Trottier; Linda J Burns; Todd E DeFor; Sarah Cooley; Navneet S Majhail
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 7.  Iron overload in the HCT patient: a review.

Authors:  Pavan Tenneti; Aleksander Chojecki; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-03-29       Impact factor: 5.174

Review 8.  Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes.

Authors:  Sachi Jain Taran; Rakesh Taran
Journal:  South Asian J Cancer       Date:  2015 Oct-Dec

9.  Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia.

Authors:  Seom Gim Kong; Seri Jeong; Sangjin Lee; Jee-Yeong Jeong; Da Jung Kim; Ho Sup Lee
Journal:  BMC Cancer       Date:  2021-02-18       Impact factor: 4.430

10.  Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.

Authors:  E M P Cremers; A van Biezen; L C de Wreede; M Scholten; A Vitek; J Finke; U Platzbecker; D Beelen; R Schwerdtfeger; L Volin; N Harhalakis; N Blijlevens; A Nagler; N Kröger; T de Witte
Journal:  Ann Hematol       Date:  2016-09-20       Impact factor: 3.673
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.